Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) have received an average rating of “Hold” from the twenty-three analysts that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $22.29.

Several equities research analysts have weighed in on TEVA shares. Credit Suisse Group cut their target price on shares of Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating on the stock in a report on Thursday. Raymond James upgraded shares of Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $22.00 target price on the stock in a report on Thursday. Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday. Wells Fargo & Co reiterated a “hold” rating and issued a $20.00 target price (down from $24.00) on shares of Teva Pharmaceutical Industries in a report on Thursday. They noted that the move was a valuation call. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Monday, February 11th.

In related news, VP Hafrun Fridriksdottir sold 1,643 shares of the firm’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $15.70, for a total transaction of $25,795.10. Following the sale, the vice president now directly owns 13,469 shares in the company, valued at $211,463.30. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Notaristefani Carlo De sold 5,041 shares of the firm’s stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $17.88, for a total transaction of $90,133.08. Following the sale, the vice president now owns 17,162 shares in the company, valued at $306,856.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 7,617 shares of company stock worth $136,230. 0.43% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the business. Bruderman Asset Management LLC increased its stake in Teva Pharmaceutical Industries by 2,175.0% in the 4th quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock valued at $36,000 after buying an additional 2,262 shares during the last quarter. Rational Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $49,000. Capital Investment Advisory Services LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $56,000. Quadrant Capital Group LLC increased its stake in Teva Pharmaceutical Industries by 420.3% in the 4th quarter. Quadrant Capital Group LLC now owns 5,541 shares of the company’s stock valued at $80,000 after buying an additional 4,476 shares during the last quarter. Finally, Whittier Trust Co. increased its stake in Teva Pharmaceutical Industries by 35.4% in the 4th quarter. Whittier Trust Co. now owns 5,481 shares of the company’s stock valued at $84,000 after buying an additional 1,434 shares during the last quarter. Hedge funds and other institutional investors own 62.11% of the company’s stock.

Shares of TEVA stock opened at $17.98 on Wednesday. Teva Pharmaceutical Industries has a 52-week low of $14.59 and a 52-week high of $25.96. The company has a market capitalization of $18.28 billion, a price-to-earnings ratio of 6.42, a price-to-earnings-growth ratio of 7.20 and a beta of 1.46. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, February 13th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.53. Teva Pharmaceutical Industries had a negative net margin of 11.40% and a positive return on equity of 18.57%. The firm had revenue of $4.56 billion for the quarter, compared to analysts’ expectations of $4.52 billion. During the same period last year, the firm earned $0.93 earnings per share. The business’s revenue for the quarter was down 15.5% on a year-over-year basis. As a group, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.65 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: Liquidity

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.